NCT00674843

Brief Summary

The muscular dystrophies (MD) are a group of more than 30 neuromuscular disorders that are characterized by progressive skeletal muscle weakness, defects in muscle proteins and the death of muscle cells and tissue. This study will investigate the use of far infrared radiation for managing muscular dystrophies.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
4

participants targeted

Target at below P25 for phase_1

Timeline
Completed

Started May 2008

Typical duration for phase_1

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2008

Completed
5 days until next milestone

First Submitted

Initial submission to the registry

May 6, 2008

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 8, 2008

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2010

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2010

Completed
Last Updated

August 17, 2009

Status Verified

August 1, 2009

Enrollment Period

2 years

First QC Date

May 6, 2008

Last Update Submit

August 14, 2009

Conditions

Muscular Dystrophies

Keywords

MYOTONIC DYSTROPHYMYOPATHIESDistal MyopathiesMuscular Dystrophy, DuchennePhosphorylase Deficiency (McArdle Disease)

Outcome Measures

Primary Outcomes (1)

  • Management and Cure of muscular dystrophies

    2 Years

Secondary Outcomes (1)

  • Rehabilitation of people with muscular dystrophies

    2 Years

Study Arms (1)

1

EXPERIMENTAL

Radiation: Far Infrared Radiation (5μm to 20μm wavelength)

Radiation: Far Infrared Radiation

Interventions

Far Infrared RadiationRADIATION

Radiation: Far Infrared Radiation (5μm to 20μm wavelength) Far Infrared radiation for 30 to 40 minutes per treatment session.

1

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Persons with muscular dystrophies

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Centre for Incurable Diseases

Toronto, Ontario, M4V 1L5, Canada

Location

MeSH Terms

Conditions

Muscular DystrophiesMyotonic DystrophyMuscular DiseasesDistal MyopathiesMuscular Dystrophy, DuchenneGlycogen Storage Disease Type V

Condition Hierarchy (Ancestors)

Muscular Disorders, AtrophicMusculoskeletal DiseasesNeuromuscular DiseasesNervous System DiseasesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesMyotonic DisordersHeredodegenerative Disorders, Nervous SystemNeurodegenerative DiseasesGenetic Diseases, X-LinkedGlycogen Storage DiseaseCarbohydrate Metabolism, Inborn ErrorsMetabolism, Inborn ErrorsMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

  • Ken Nedd, M.D.

    GAAD Medical Research Institute Inc.

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

May 6, 2008

First Posted

May 8, 2008

Study Start

May 1, 2008

Primary Completion

May 1, 2010

Study Completion

June 1, 2010

Last Updated

August 17, 2009

Record last verified: 2009-08

Locations

CA(1)